Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth C Anderson

Showing results (151-160 of 868) with videos related to

Pageof 87
Sort By:
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|July 16, 2005
Perspectives for combination therapy to overcome drug-resistant multiple myelomaLaurence Catley, Yu-Tzu Tai, Dharminder Chauhan, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 6, 2007
The emerging role of novel therapies for the treatment of relapsed myelomaPaul G Richardson, Teru Hideshima, Constantine Mitsiades, et al.
Expert Review of Anticancer Therapy|August 24, 2006
Lenalidomide in multiple myelomaPaul G Richardson, Constantine Mitsiades, Teru Hideshima, et al.
Expert Opinion on Investigational Drugs|October 10, 2007
The therapeutic role of targeting protein kinase C in solid and hematologic malignanciesKlaus Podar, Marc S Raab, Dharminder Chauhan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2005
Intracellular protein degradation and its therapeutic implicationsTeru Hideshima, James E Bradner, Dharminder Chauhan, et al.
Annual Review of Medicine|January 18, 2006
Bortezomib: proteasome inhibition as an effective anticancer therapyPaul G Richardson, Constantine Mitsiades, Teru Hideshima, et al.
Journal of the National Cancer Institute|March 4, 2008
Re: When you look matters: the effect of assessment schedule on progression-free survivalPaul G Richardson, Ruben Niesvizky, Kenneth C Anderson, et al.
Current Pharmaceutical Biotechnology|November 2, 2006
Recent advances in the treatment of Multiple MyelomaHiroshi Yasui, Teru Hideshima, Paul G Richardson, et al.
Nature Reviews. Clinical Oncology|January 10, 2018
The bone-marrow niche in MDS and MGUS: implications for AML and MMIrene M Ghobrial, Alexandre Detappe, Kenneth C Anderson, et al.
Cell Cycle (Georgetown, Tex.)|October 7, 2004
Mcl-1 regulation and its role in multiple myelomaSteven Le Gouill, Klaus Podar, Jean-Luc Harousseau, et al.
Pageof 87

Showing results (151-160 of 868) with videos related to

Sort By:
Pageof 87
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|July 16, 2005
Perspectives for combination therapy to overcome drug-resistant multiple myelomaLaurence Catley, Yu-Tzu Tai, Dharminder Chauhan, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 6, 2007
The emerging role of novel therapies for the treatment of relapsed myelomaPaul G Richardson, Teru Hideshima, Constantine Mitsiades, et al.
Expert Review of Anticancer Therapy|August 24, 2006
Lenalidomide in multiple myelomaPaul G Richardson, Constantine Mitsiades, Teru Hideshima, et al.
Expert Opinion on Investigational Drugs|October 10, 2007
The therapeutic role of targeting protein kinase C in solid and hematologic malignanciesKlaus Podar, Marc S Raab, Dharminder Chauhan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2005
Intracellular protein degradation and its therapeutic implicationsTeru Hideshima, James E Bradner, Dharminder Chauhan, et al.
Annual Review of Medicine|January 18, 2006
Bortezomib: proteasome inhibition as an effective anticancer therapyPaul G Richardson, Constantine Mitsiades, Teru Hideshima, et al.
Journal of the National Cancer Institute|March 4, 2008
Re: When you look matters: the effect of assessment schedule on progression-free survivalPaul G Richardson, Ruben Niesvizky, Kenneth C Anderson, et al.
Current Pharmaceutical Biotechnology|November 2, 2006
Recent advances in the treatment of Multiple MyelomaHiroshi Yasui, Teru Hideshima, Paul G Richardson, et al.
Nature Reviews. Clinical Oncology|January 10, 2018
The bone-marrow niche in MDS and MGUS: implications for AML and MMIrene M Ghobrial, Alexandre Detappe, Kenneth C Anderson, et al.
Cell Cycle (Georgetown, Tex.)|October 7, 2004
Mcl-1 regulation and its role in multiple myelomaSteven Le Gouill, Klaus Podar, Jean-Luc Harousseau, et al.
Pageof 87